Therapeutic potential of targeting galectins – A biomaterials-focused perspective
Authors:
Open Access
- 18 May 2022
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 286, 121585
Abstract
No abstract availableKeywords
This publication has 195 references indexed in Scilit:
- A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced DiseaseCancer Research, 2013
- Inhibiting galectin-1 reduces murine lung metastasis with increased CD4+ and CD8+ T cells and reduced cancer cell adherenceClinical & Experimental Metastasis, 2012
- Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasionNature, 2012
- Ablation of a galectin preferentially expressed in adipocytes increases lipolysis, reduces adiposity, and improves insulin sensitivity in miceProceedings of the National Academy of Sciences, 2011
- When Galectins Recognize Glycans: From Biochemistry to Physiology and Back AgainBiochemistry, 2011
- Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic responseJournal of Experimental Medicine, 2010
- Development of Monocytes, Macrophages, and Dendritic CellsScience, 2010
- Functions of cell surface galectin-glycoprotein latticesCurrent Opinion in Structural Biology, 2007
- Human galectin-1, -2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cellsBlood, 2006
- The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunityNature Immunology, 2005